Clinical Trial Update: Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)

View source ↗

Summary

This update reports a completed Spain-based study (PROMISE) evaluating adalimumab (HUMIRA) for moderate-to-severe chronic plaque psoriasis, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Moderate-to-severe Chronic Plaque Psoriasis | Status: COMPLETED | Results posted: 2016-01-06